Received Mar 18, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| TYP | TYPHOID LIVE ORAL TY21A (VIVOTIF) | BERNA BIOTECH, LTD. | UNK | Unknown | — |
Patient took two doses on consecutive days; Case reference number US-BN-2025-001070 is a spontaneous case initially received from a pharmacist via Communication (reference number: USBAV25-1388) on 13-Jun-2025 and concerns a patient of unspecified age and gender. The patient's medical history and concomitant medication details were not provided. On an unspecified date, the patient took a dose of the Vivotif vaccine (batch number: unknown) at an unknown dose, route or site of administration, for an unknown indication. On an unspecified date, an unknown amount of time from the dose of Vivotif, the patient another dose, (batch number: unknown) at an unknown dose, route or site of administration. Patient took two doses on consecutive days (explicitly coded as 'inappropriate schedule of vaccine administered'). At the time of the initial report, it was unknown if the patient experienced any adverse events due to Vivotif. No further information was provided.; Reporter's Comments: A patient of unspecified age and gender took two doses of Vivotif for an unknown indication on consecutive days, which is considered as inappropriate schedule of vaccine administered. It was unknown if the patient experienced any adverse events due to Vivotif. Inappropriate schedule of product administration is considered as listed per company convention. The patient's medical history and concomitant medication details were not provided. Inappropriate schedule of product administration is not related to the suspect vaccine, but to a human factor. This case is considered as non-serious.; Sender's Comments: A patient of unspecified age and gender took two doses of Vivotif for an unknown indication on consecutive days, which is considered as inappropriate schedule of vaccine administered. It was unknown if the patient experienced any adverse events due to Vivotif. Inappropriate schedule of product administration is considered as listed per company convention. The patient's medical history and concomitant medication details were not provided. Inappropriate schedule of product administration is not related to the suspect vaccine, but to a human factor. This case is considered as non-serious.
Comments: NONE